Press Releases

BIOMS MEDICAL TO PRESENT AT FEDERATION OF CLINICAL IMMUNOLOGY SOCIETIES 2006

Edmonton, Alberta, June 2, 2006 - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that Mark Krantz, PhD, Vice President Scientific Affairs, BioMS Medical, will present at FOCIS 2006 in San Francisco, California.

WHEN: Sunday, June 4th, 2006 at 3:45 pm (Pacific Time)
WHERE: San Francisco Marriott, San Francisco, CA

Dr. Krantz will be presenting on the treatment of multiple sclerosis (MS) by antigen specific tolerance induction with synthetic peptide MBP8298.

BioMS Medical’s lead product candidate, MBP8298, is a synthetic peptide that consists of 17 amino acids linked in a sequence identical to that of a portion of human myelin basic protein (MBP). MBP8298 has been developed for the treatment of MS. BioMS Medical is currently enrolling patients across Canada, the U.K., Sweden, and Denmark in its pivotal phase II/III clinical trial evaluating MBP8298 for the treatment of secondary progressive multiple sclerosis (SPMS).

About FOCIS 2006

FOCIS draws the best clinician scientists from around the world to present and partake in the scientific program, bringing together cutting-edge science from various disease fields related to clinical immunology. The diverse audience is made up of scientists, clinicians, and researchers interested in the broad-based implications of their work.

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.